HomeCompareHEXPF vs ABBV

HEXPF vs ABBV: Dividend Comparison 2026

HEXPF yields 6451.61% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HEXPF wins by $746046519283998.75M in total portfolio value
10 years
HEXPF
HEXPF
● Live price
6451.61%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$746046519283998.88M
Annual income
$723,972,000,481,503,000,000.00
Full HEXPF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — HEXPF vs ABBV

📍 HEXPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHEXPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HEXPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HEXPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HEXPF
Annual income on $10K today (after 15% tax)
$548,387.10/yr
After 10yr DRIP, annual income (after tax)
$615,376,200,409,277,500,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, HEXPF beats the other by $615,376,200,409,277,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HEXPF + ABBV for your $10,000?

HEXPF: 50%ABBV: 50%
100% ABBV50/50100% HEXPF
Portfolio after 10yr
$373023259641999.50M
Annual income
$361,986,000,240,751,500,000.00/yr
Blended yield
97.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HEXPF
No analyst data
Altman Z
-17.6
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HEXPF buys
0
ABBV buys
0
No recent congressional trades found for HEXPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHEXPFABBV
Forward yield6451.61%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$746046519283998.88M$104.7K
Annual income after 10y$723,972,000,481,503,000,000.00$25,725.73
Total dividends collected$744564070034128.50M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HEXPF vs ABBV ($10,000, DRIP)

YearHEXPF PortfolioHEXPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$655,861$645,161.29$11,559$438.51+$644.3KHEXPF
2$40,247,222$39,545,450.12$13,494$640.86+$40.23MHEXPF
3$2,311,031,117$2,267,966,589.88$15,951$945.97+$2311.02MHEXPF
4$124,181,822,284$121,709,018,988.28$19,152$1,413.89+$124181.80MHEXPF
5$6,244,985,365,552$6,112,110,815,708.32$23,443$2,146.38+$6244985.34MHEXPF
6$293,945,892,838,957$287,263,758,497,816.90$29,391$3,321.96+$293945892.81MHEXPF
7$12,951,203,390,243,552$12,636,681,284,905,868.00$37,948$5,265.87+$12951203390.21MHEXPF
8$534,203,501,715,883,900$520,345,714,088,323,260.00$50,795$8,596.74+$534203501715.83MHEXPF
9$20,630,391,404,201,763,000$20,058,793,657,365,766,000.00$71,034$14,549.41+$20630391404201.69MHEXPF
10$746,046,519,283,998,900,000$723,972,000,481,503,000,000.00$104,715$25,725.73+$746046519283998.75MHEXPF

HEXPF vs ABBV: Complete Analysis 2026

HEXPFStock

Angel Wing Metals Inc., a minerals exploration company, focuses on exploring early-stage precious metals properties in Canada and Mexico. Its flagship asset is the El Grande gold project that covers approximately 550 square kilometers in the southern extension of the prolific Sierra Madre Occidental gold-silver belt in the state of Nayarit, Mexico. The company also owns two early-stage gold exploration projects in Northwestern Ontario. The company was formerly known as Huntington Exploration Inc. and changed its name to Angel Wing Metals Inc. in May 2022. Angel Wing Metals Inc. was incorporated in 1995 and is based in Toronto, Canada.

Full HEXPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HEXPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HEXPF vs SCHDHEXPF vs JEPIHEXPF vs OHEXPF vs KOHEXPF vs MAINHEXPF vs JNJHEXPF vs MRKHEXPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.